Literature DB >> 25637406

Risk factors associated with unfavorable short-term treatment outcome in patients with documented Pseudomonas aeruginosa infection.

V Paul DiMondi1, Mary L Townsend, Richard H Drew.   

Abstract

BACKGROUND: Invasive infections with Pseudomonas aeruginosa (PA) are associated with significant morbidity and mortality. While risk factors for mortality have been identified, their influence on short-term outcomes impacting treatment selection has not been reported.
OBJECTIVES: The objective of this study was to evaluate the relationship between select patient- and treatment-related factors and short-term outcomes in patients with PA pneumonia and/or bacteremia.
SETTING: Large academic medical center in the United States.
METHODS: This IRB-approved single-center, retrospective case-cohort study included patients >18 years of age with culture-confirmed PA bacteremia and/or pneumonia receiving antimicrobial agent(s) active against PA. MAIN OUTCOME MEASURE: Risk of unfavorable short-term treatment result.
RESULTS: The population consisted of 117 patients (40 [34 %] and 77 [66 %] in the unfavorable and not-unfavorable groups, respectively). Baseline characteristics including age (mean of 63 years), gender (55 % male), Charlson score, creatinine clearance, and body mass index were comparable between groups. Piperacillin/tazobactam was the most common monotherapy antibiotic (46 and 33 % in unfavorable and not-unfavorable groups, respectively). Combination therapy primarily consisted of a beta-lactam plus ciprofloxacin in both unfavorable (10 %) and not-unfavorable (20 %) outcome groups. The preliminary regression model indicated that SIRS, direct ICU admission, and vasopressor therapy were associated with an unfavorable outcome. In addition, patients who received more than two active antimicrobials had a reduced risk of an unfavorable outcome. The final regression model revealed that vasopressor therapy (odds ratio [OR] 6.0; 95 % confidence interval [95 % CI] 2.3, 17) was associated with an unfavorable outcome, while receipt of greater than two active antibiotics was associated with a reduced risk of an unfavorable outcome (OR 0.26; 95 % CI 0.07, 0.83).
CONCLUSIONS: Treatment with more than two agents with activity against PA was associated with a reduced risk of an unfavorable short-term treatment outcome in patients with bacteremia and/or pneumonia.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25637406     DOI: 10.1007/s11096-015-0067-6

Source DB:  PubMed          Journal:  Int J Clin Pharm


  22 in total

Review 1.  Prescribing guidelines for severe Pseudomonas infections.

Authors:  Helen Giamarellou
Journal:  J Antimicrob Chemother       Date:  2002-02       Impact factor: 5.790

2.  Pseudomonas aeruginosa bacteremia: risk factors for mortality and influence of delayed receipt of effective antimicrobial therapy on clinical outcome.

Authors:  Cheol-In Kang; Sung-Han Kim; Hong-Bin Kim; Sang-Won Park; Young-Ju Choe; Myoung-Don Oh; Eui-Chong Kim; Kang-Won Choe
Journal:  Clin Infect Dis       Date:  2003-08-23       Impact factor: 9.079

3.  The combination of meropenem and levofloxacin is synergistic with respect to both Pseudomonas aeruginosa kill rate and resistance suppression.

Authors:  Arnold Louie; Caroline Grasso; Nadzeya Bahniuk; Brian Van Scoy; David L Brown; Robert Kulawy; G L Drusano
Journal:  Antimicrob Agents Chemother       Date:  2010-04-05       Impact factor: 5.191

4.  Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia.

Authors: 
Journal:  Am J Respir Crit Care Med       Date:  2005-02-15       Impact factor: 21.405

5.  A new method of classifying prognostic comorbidity in longitudinal studies: development and validation.

Authors:  M E Charlson; P Pompei; K L Ales; C R MacKenzie
Journal:  J Chronic Dis       Date:  1987

6.  Pseudomonas aeruginosa bloodstream infection: importance of appropriate initial antimicrobial treatment.

Authors:  Scott T Micek; Ann E Lloyd; David J Ritchie; Richard M Reichley; Victoria J Fraser; Marin H Kollef
Journal:  Antimicrob Agents Chemother       Date:  2005-04       Impact factor: 5.191

7.  Should morbidity replace mortality as an endpoint for clinical trials in intensive care?

Authors:  A J Petros; J C Marshall; H K van Saene
Journal:  Lancet       Date:  1995-02-11       Impact factor: 79.321

8.  Effect of empirical treatment with moxifloxacin and meropenem vs meropenem on sepsis-related organ dysfunction in patients with severe sepsis: a randomized trial.

Authors:  Frank M Brunkhorst; Michael Oppert; Gernot Marx; Frank Bloos; Katrin Ludewig; Christian Putensen; Axel Nierhaus; Ulrich Jaschinski; Andreas Meier-Hellmann; Andreas Weyland; Matthias Gründling; Onnen Moerer; Reimer Riessen; Armin Seibel; Maximilian Ragaller; Markus W Büchler; Stefan John; Friedhelm Bach; Claudia Spies; Lorenz Reill; Harald Fritz; Michael Kiehntopf; Evelyn Kuhnt; Holger Bogatsch; Christoph Engel; Markus Loeffler; Marin H Kollef; Konrad Reinhart; Tobias Welte
Journal:  JAMA       Date:  2012-06-13       Impact factor: 56.272

9.  Morbidity associated with Pseudomonas aeruginosa bloodstream infections.

Authors:  Marc H Scheetz; Michael Hoffman; Maureen K Bolon; Grant Schulert; Wendy Estrellado; Ioannis G Baraboutis; Padman Sriram; Minh Dinh; Linda K Owens; Alan R Hauser
Journal:  Diagn Microbiol Infect Dis       Date:  2009-04-02       Impact factor: 2.803

Review 10.  Clinical review: Circulatory shock--an update: a tribute to Professor Max Harry Weil.

Authors:  Jean-Louis Vincent; Can Ince; Jan Bakker
Journal:  Crit Care       Date:  2012-11-20       Impact factor: 9.097

View more
  4 in total

1.  Antimicrobial combination treatment including ciprofloxacin decreased the mortality rate of Pseudomonas aeruginosa bacteraemia: a retrospective cohort study.

Authors:  M Paulsson; A Granrot; J Ahl; J Tham; F Resman; K Riesbeck; F Månsson
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2017-01-21       Impact factor: 3.267

2.  Pharmacokinetic-pharmacodynamic analysis of ciprofloxacin in elderly Chinese patients with lower respiratory tract infections caused by Gram-negative bacteria.

Authors:  Xiao-Yan Gai; Shi-Ning Bo; Ning Shen; Qing-Tao Zhou; An-Yue Yin; Wei Lu
Journal:  Chin Med J (Engl)       Date:  2019-03-20       Impact factor: 2.628

3.  Risk factors for early postoperative cognitive dysfunction after colorectal surgery.

Authors:  Yuan Zhang; Hong-Guang Bao; Yun-Luo Lv; Yan-Na Si; Liu Han; Hong-Yu Wang; Yu-Jie Gao; Wei-Qing Jiang; Chen Zhang
Journal:  BMC Anesthesiol       Date:  2019-01-08       Impact factor: 2.217

4.  Mortality associated with carbapenem-susceptible and Verona Integron-encoded Metallo-β-lactamase-positive Pseudomonas aeruginosa bacteremia.

Authors:  Marjolein C Persoon; Anne F Voor In't Holt; Cornelia C H Wielders; Diederik Gommers; Margreet C Vos; Juliëtte A Severin
Journal:  Antimicrob Resist Infect Control       Date:  2020-02-03       Impact factor: 4.887

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.